Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
Praxis Precision Medicines Inc Ordinary Shares PRAX
News
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Says FDA Extends Review of Relutrigine Application
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine
Praxis Shares Rise on Ulixacaltamide Breakthrough Designation
Praxis Gets FDA Breakthrough Designation for Essential Tremor Drug
Praxis Converts Elsunersen Study to Single-Arm Design After FDA Meeting
Praxis Completes FDA Meeting for Tremor Treatment, Reports Positive Results for Epilepsy Drug
Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
United States